APA

Giusti B., Gori A. M., Marcucci R., Saracini C., Sestini I., Paniccia R., Valente S., Antoniucci D., Abbate R. & Gensini G. F. (20080122). Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. : Pharmacogenetics and genomics.

Chicago

Giusti Betti, Gori Anna Maria, Marcucci Rossella, Saracini Claudia, Sestini Ilaria, Paniccia Rita, Valente Serafina, Antoniucci Davide, Abbate Rosanna and Gensini Gian Franco. 20080122. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. : Pharmacogenetics and genomics.

Harvard

Giusti B., Gori A. M., Marcucci R., Saracini C., Sestini I., Paniccia R., Valente S., Antoniucci D., Abbate R. and Gensini G. F. (20080122). Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. : Pharmacogenetics and genomics.

MLA

Giusti Betti, Gori Anna Maria, Marcucci Rossella, Saracini Claudia, Sestini Ilaria, Paniccia Rita, Valente Serafina, Antoniucci Davide, Abbate Rosanna and Gensini Gian Franco. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. : Pharmacogenetics and genomics. 20080122.